CONMED Corporation (CNMD) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mixed picture: improved profitability, positive revenue growth guidance, and margin improvements are balanced by concerns over increased interest expenses and supply chain issues. The Q&A section reveals management's vague responses on key metrics, which could create uncertainty. The company's market cap suggests moderate price sensitivity. Overall, despite some positive aspects, the lack of clarity on critical issues and potential financial headwinds lead to a neutral prediction, with stock price expected to remain stable within a -2% to 2% range over the next two weeks.
Key Financial Performance
Total Sales $317 million, a decrease of 1.3% year-over-year. Excluding the impact of the exit from gastroenterology product lines, total sales increased 3.8% year-over-year as reported and 2.1% in constant currency. The decline was due to the strategic exit from the GI business.
Orthopedics Sales Grew 4.5% on a constant currency basis year-over-year. This growth reflects improving supply reliability and strength in core platforms.
General Surgery Sales Declined 7.4% in constant currency but were flat after adjusting for the gastroenterology exit. The decline was primarily due to the exit from the GI business.
Adjusted Net Income $27.1 million, a decrease of 8.5% year-over-year. The decrease was impacted by the exit of the GI business.
Adjusted Diluted Net Earnings Per Share $0.89, a decrease of 6.3% year-over-year. The decrease was impacted by the exit of the GI business.
Adjusted Gross Margin 57.4%, which is 100 basis points higher than the prior year quarter. This increase was driven by favorable product mix and positive foreign currency impact.
Adjusted Research and Development Expense 4.8% of sales, 80 basis points higher than the prior year quarter. This increase was driven primarily by increased investment into key growth drivers.
Adjusted SG&A Expenses 40.0% of sales, 130 basis points higher than the prior year quarter. The increase was due to higher expenses in the first quarter.
Interest Expense $5.8 million in the first quarter.
Adjusted Effective Tax Rate 24.2% in Q1.
GAAP Net Income $13.8 million compared to $6.0 million in 2025. The increase reflects improved profitability despite the GI business exit.
GAAP Earnings Per Diluted Share $0.45 this quarter compared to $0.19 a year ago. The increase reflects improved profitability despite the GI business exit.
Cash Balance $35.0 million at March 31 compared to $40.8 million at December 31.
Accounts Receivable Days 65 days at March 31 compared to 62 days at March of 2025 and 60 days at December 31.
Inventory Days 246 days at quarter end compared to 222 days a year ago and 207 on December 31. The increase was due to purposely building more inventory to focus on service levels.
Long-term Debt $860.2 million versus $834.2 million as of December 31.
Leverage Ratio 3.1x at March 31.
Cash Flow from Operations $13.5 million compared to $41.5 million in the first quarter of 2025. The decrease reflects higher cash outlays in Q1.
Capital Expenditures $2.9 million compared to $3.8 million a year ago.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
AirSeal: AirSeal is a clinical insufflation platform with over 10,000 systems globally. It supports robotic and laparoscopic surgeries, with a significant opportunity in the underpenetrated laparoscopic market. It is expected to deliver high single-digit to low double-digit growth over the long term.
Buffalo Filter: This smoke evacuation platform benefits from legislative trends, with 20 U.S. states adopting smoke-free operating room laws. International traction is growing in Nordic countries, Canada, and Australia. The PlumeSafe X5 product, launched in 2025, is gaining traction in outpatient and ambulatory environments.
BioBrace: BioBrace is a differentiated solution in orthopedic soft tissue repair, combining structural reinforcement and biologic healing. It is supported by over 30 published studies and ongoing clinical trials, with a long runway for growth as it becomes embedded in surgical workflows.
Geographic Expansion: Buffalo Filter is gaining traction internationally, particularly in Nordic countries, Canada, and Australia.
Divestment of GI Products: The company divested its gastroenterology product lines to focus on higher growth, higher-margin offerings. Transition services will be provided through 2027.
Supply Chain Improvements: Supply chain performance improved, enabling consistent service and supporting sustained growth. Orthopedics achieved mid-single-digit growth for three consecutive quarters.
Focus on Key Growth Platforms: The company is strategically focusing on AirSeal, Buffalo Filter, and BioBrace platforms, which are central to its long-term strategy and margin expansion.
Capital Allocation: The company is balancing investments in innovation, manufacturing, and acquisitions while maintaining financial discipline and returning capital to shareholders.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Divestment of GI Products: The company has divested certain gastroenterology (GI) products and plans to provide transition services under TSAs through 2027. This strategic decision could lead to short-term revenue reductions and operational challenges during the transition period.
Decline in General Surgery Sales: General surgery sales declined 7.4% in constant currency, with organic international sales decreasing by 3.3%. This decline could impact overall revenue and growth in this segment.
Supply Chain Challenges: Although supply chain performance has improved, the company is still working to build inventory and expand capacity, which could pose risks to operational efficiency and cost management.
Debt and Leverage: The company’s long-term debt increased to $860.2 million, with a leverage ratio of 3.1x. Refinancing plans in Q2 could increase interest expenses, impacting adjusted EPS by at least $0.10.
Interest Expense Increase: Refinancing debt with bank loans instead of convertible notes is expected to increase interest expenses, potentially affecting profitability.
OEM Smoke Products Performance: OEM smoke products were a significant headwind in Q1, with lumpy performance that could continue to impact general surgery sales.
Inventory Management: Inventory days increased to 246 from 222 a year ago, reflecting a deliberate build-up to improve service levels. This could tie up capital and affect cash flow.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Organic Growth Expectation for 2026: Raised to 5.0% to 6.5% from the prior range of 4.5% to 6.0%.
Foreign Exchange Impact: Expected to be a tailwind to revenue of between 40 and 50 basis points.
GI Product Lines Revenue Guidance for 2026: Reduced to $14.5 million to $17.5 million from the prior estimate of $21 million to $25 million due to faster-than-anticipated sales agreements.
Reported Revenue for 2026: Expected to be between $1.35 billion to $1.375 billion.
Q2 2026 Revenue Guidance: Expected to be between $336 million and $340 million.
Debt Refinancing Impact: Refinancing with bank debt in Q2 may increase full-year adjusted interest expense, impacting adjusted EPS by at least $0.10.
Adjusted EPS Guidance for 2026: Unchanged at $4.30 to $4.45.
Q2 2026 Adjusted EPS Guidance: Expected to be between $1.09 and $1.14.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Buyback Program: In Q1, the company repurchased approximately 858,000 shares for a total of $37.4 million. The leverage ratio at the end of the quarter was 3.1x, and the company expects this ratio to hold at roughly 3x as it balances debt leverage and share buybacks.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the strategy for debt refinancing and mitigating potential EPS dilution in 2026 and 2027?
A:The company is starting discussions with banking partners and has decided against issuing new convertible notes due to low med tech multiples. This raises the cost of capital slightly, estimated at least $0.10, but the strength of the business allows them to maintain EPS despite increased interest expense.
Q:What is the impact of inflationary pressures on margins and the margin guidance for the year?
A:Inflationary pressures on commodities like oil and gold are affecting costs, but the company is working with vendors and supply chains to mitigate these. Macro influences on costs are included in the guidance, and no additional impact is expected on margins.
Q:What was the attach rate of AirSeal to DV5 during the quarter?
A:The company did not state the exact attach rate for the quarter but mentioned it remains within the previously guided range of 10% to 20%.
Q:What is the visibility into state legislation on operating rooms (ORs) and its potential impact?
A:20 states have enacted legislation covering 45% of U.S. hospitals and 51% of the population. 13 additional states have pending bills, with Maryland and Massachusetts most likely to pass. The company sees legislation and clinical benefits driving adoption of smoke evacuation systems.
Q:What is the bridge for the second quarter's expected performance and growth drivers?
A:The company expects growth in orthopedics, BioBrace, international markets, AirSeal, and smoke evacuation. Orthopedics and BioBrace are accelerating, international markets are recovering from a strong Q4, and AirSeal and smoke evacuation are expected to grow in Q2.
Q:What is the outlook for gross margin improvement in 2026?
A:Gross margin improved by 100 basis points in Q1, reaching the top end of the full-year guidance range of 50 to 100 basis points. The company expects similar improvement in each quarter of 2026.
Q:What is the potential for growth in the laparoscopic market for AirSeal?
A:AirSeal has a 6%-7% penetration rate in the U.S. laparoscopic market, which includes over 3 million procedures annually. The company is focusing on standardization in complex surgeries like colorectal and hysterectomy. AirSeal unit placements increased by over 50% in Q1 compared to Q1 2025.
Q:What progress has been made in resolving supply chain issues, and what is the expected timeline for recovery?
A:Supply chain improvements made at the end of 2025 have been sustained, allowing growth in orthopedics. While not all lost business will be recovered quickly, strong hospital relationships and market opportunities are expected to drive growth over time.
Q:What is the outlook for Buffalo Filter's OEM business and its impact on smoke evacuation?
A:The OEM business is smaller than the direct business and is expected to continue shrinking. The direct smoke evacuation business grew in Q1, and total smoke evacuation is expected to grow in high single digits to low double digits in 2026.
Q:What is the impact of increased interest expense on EPS guidance for 2026 and beyond?
A:The increased interest expense is estimated to have at least a $0.10 impact, but the company is maintaining its 2026 EPS guidance. The impact on 2027 is uncertain, as the company may access the convertible market or adjust strategies based on cash flow and market conditions.
Q:Review of Unclear Management Responses
A:Management avoided providing precise details on the attach rate of AirSeal to DV5, stating only that it remains within the 10%-20% range. Additionally, they were vague about the exact impact of increased interest expense on 2027 EPS, emphasizing uncertainty and the potential for changes in strategy.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Academy Orthopedic
AirSeal base
AirSeal case
AirSeal differentiation
AirSeal role
AirSeal surgeon
Australia product
BioBrace life
BioBrace patient
BioBrace surgeon
BioBrace workflow
CFO update
CONMED discipline
Canada Australia
FDA implant
GI platform
GI product
Orthopedics
agreement GI
center
confidence
decision
environment
exit
focus
footprint
gastroenterology
insufflation
investment
manufacturing
market AirSeal
opportunity platform
platform term
priority
repair surgeon
sale currency
service
state
term value
traction
CNMD Transcript
CONMED Corporation (CNMD) Q1 2026 Earnings Call Transcript
Unknown4-30
The earnings call presents a mixed picture: improved profitability, positive revenue growth guidance, and margin improvements are balanced by concerns over increased interest expenses and supply chain issues. The Q&A section reveals management's vague responses on key metrics, which could create uncertainty. The company's market cap suggests moderate price sensitivity. Overall, despite some positive aspects, the lack of clarity on critical issues and potential financial headwinds lead to a neutral prediction, with stock price expected to remain stable within a -2% to 2% range over the next two weeks.
CONMED Corporation (CNMD) Q4 2025 Earnings Call Transcript
Positive1-28
The earnings call highlights strong financial performance with EPS growth and improved cash flow. The transition to a share repurchase program and strategic focus on high-margin platforms are positive indicators. The Q&A reveals confidence in growth opportunities and strategic focus, despite minor portfolio adjustments. The positive sentiment is reinforced by strong OUS growth and a balanced approach to M&A and R&D investments. The market cap suggests a moderate reaction, leading to a positive stock price movement prediction.
CONMED Corporation (CNMD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-12
CONMED Corporation (CNMD) Q3 2025 Earnings Call Transcript
Unknown11-5
The earnings call presents a mixed picture: while there is a slight increase in EPS and cash flow, there are concerns about declining gross margins, a significant drop in GAAP net income, and management's reluctance to provide future guidance. The leverage ratio improvement and AirSeal's growth are positives, but the orthopedic backlog and tariff impacts are negatives. The market cap suggests moderate volatility, leading to a neutral stock price prediction.
CNMD Slides
CNMD Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
